Globe Newswire
JEDDAH, Saudi Arabia, June 02, 2024 (GLOBE NEWSWIRE) -- In an era where healthcare innovation is paramount, KFSHRC Jeddah has made headway in the treatment of severe Xanthoma through the deployment of a modified plasma exchange protocol. This milestone underscores KFSHRC's position as a trailblazer in healthcare innovation and patient care, particularly in addressing complex cases.
Xanthoma, characterized by the accumulation of triglyceride-filled deposits beneath... (continue reading...)
JEDDAH, Saudi Arabia, June 02, 2024 (GLOBE NEWSWIRE) -- In an era where healthcare innovation is paramount, KFSHRC Jeddah has made headway in the treatment of severe Xanthoma through the deployment of a modified plasma exchange protocol. This milestone underscores KFSHRC's position as a trailblazer in healthcare innovation and patient care, particularly in addressing complex cases.
Xanthoma, characterized by the accumulation of triglyceride-filled deposits beneath... (continue reading...)
DUBAI, United Arab Emirates, June 02, 2024 (GLOBE NEWSWIRE) -- OKX, a leading crypto exchange and Web3 technology company, has issued updates for June 2, 2024.
OKX Now Supports Wormhole Protocol's W Token on Ethereum Mainnet
OKX is pleased to announce that it now supports Wormhole Protocol's W Token on Ethereum. This means OKX customers can now deposit and withdraw W via the Ethereum mainnet.
The Wormhole Protocol is a pivotal player in the world of blockchain... (continue reading...)
DUBAI, United Arab Emirates, June 02, 2024 (GLOBE NEWSWIRE) -- OKX, a leading crypto exchange and Web3 technology company, has issued updates for June 2, 2024.
OKX Now Supports Wormhole Protocol's W Token on Ethereum Mainnet
OKX is pleased to announce that it now supports Wormhole Protocol's W Token on Ethereum. This means OKX customers can now deposit and withdraw W via the Ethereum mainnet.
The Wormhole Protocol is a pivotal player in the world of blockchain... (continue reading...)
Combined Workflow of Proteograph™ XT Assay and Thermo Scientific™ Orbitrap™ Astral™ Mass Spectrometer Robustly Identifies over 13,000 Protein Groups Across a Study of 2,840 Subjects
REDWOOD CITY, Calif., June 02, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, announced today that PrognomiQ has completed the largest and deepest unbiased mass spectrometry plasma... (continue reading...)
More Globe Newswire
View Older Stories-
Precede Biosciences Presents New Data at ASCO 2024 Demonstrating Accurate HER2 Status Detection Across Multiple Cancers and the Ability to Quantify ER Pathway Activation in Breast Cancer from a Simple
-
ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer
-
Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 The
-
BIIB INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024
-
NVIDIA Enables Real-Time Healthcare, Industrial and Scientific AI Applications at the Edge With Enterprise Software Support for NVIDIA IGX With Holoscan
-
NVIDIA Robotics Adopted by Industry Leaders for Development of Tens of Millions of AI-Powered Autonomous Machines
-
Robotic Factories Supercharge Industrial Digitalization as Electronic Makers Adopt NVIDIA AI and Omniverse
-
NVIDIA Brings AI Assistants to Life With GeForce RTX AI PCs
-
Computer Industry Joins NVIDIA to Build AI Factories and Data Centers for the Next Industrial Revolution
-
NVIDIA Supercharges Ethernet Networking for Generative AI
-
GDRX INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that GoodRx Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Case
-
NVIDIA NIM Revolutionizes Model Deployment, Now Available to Transform World’s Millions of Developers Into Generative AI Developers
-
NVIDIA Releases Digital Human Microservices, Paving Way for Future of Generative AI Avatars
-
Intellia Therapeutics Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)
-
William Miller Spearheads Launch of Pioneering OkayCoin Staking Protocol
-
CryptoHeap Launches Comprehensive Strategy for Crypto Staking Amidst Market Fluctuations
-
BioCryst Presents New Real-world Evidence Showing Reductions in Attack Rates in HAE Patients with Normal C1-Inhibitor after Beginning ORLADEYO® (berotralstat) Treatment
-
ePac Flexible Packaging Sets Strategy for Continued Double-Digit Growth
-
BIOGEN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Biogen Inc. and Encourages Investors to Contact the Firm
-
Heineken® Celebrates Thousands of ‘Real Hardcore Fans’ by Helping Them Take Part in the UEFA Champions League Final Trophy Celebrations For The First Time Ever
-
National Skills Champions are Honoured at the Skills Canada National Competition 2024, in Québec
-
First Federal Savings Bank and ICBA Offer Tips to Help Simplify the Homebuying Process
-
Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pretreated NSCLC EGFR Wild-type Patients and Positive Initial Data from the NSCLC EGFR Mutant Cohort
-
Union members and allies mark Injured Workers’ Day in locations across Ontario
-
Prospera Energy Inc. Announces 2023 Financial Results
-
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-sma
-
Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
-
SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical
-
Flash News: OKX Announces Position Tier Adjustments for TURBO/USDT Perpetual Futures Listing
-
ClearPoint Neuro Announces Full Market Release of SmartFrame OR™ and ClearPoint PRISM® 3T Laser Therapy System
-
Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors
-
FSLY INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Fastly, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
Y-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual Meeting
-
Ultimovacs Announces Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Y-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 ASCO Annual Meeting
-
CryptoHeap Targets Top Position in Crypto Staking Industry Before Bull Run Concludes
-
Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin) Monotherapy In Patients With Advanced Solid Tumors At ASCO 2024
-
Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer
-
OkayCoin CEO Releases Key Strategies to Maximize Investor Returns on Staking Platform
-
Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
-
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response
-
ENPH INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Enphase Energy, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib
-
VENTYX SHAREHOLDER REMINDER: BFA Law Reminds Ventyx Biosciences, Inc. (NASDAQ: VTYX) Shareholders to Contact the Firm About Ongoing Investigation
-
SQSP (NYSE) REMINDER: BFA Law Reminds Squarespace Shareholders to Inquire About Ongoing Investigation into the $44 Buyout Offer
-
SPT (NYSE) FRAUD ALERT: Sprout Social, Inc. Investors who Lost Money when Stock Plummeted 40% are Encouraged to Contact BFA Law about Upcoming Deadline
-
PATH (NYSE) INVESTOR ALERT: UiPath, Inc. Investigated for Securities Fraud After 34% Stock Drop, Contact BFA Law if You Suffered Losses
-
CERE (NASDAQ) REMINDER: BFA Law Reminds Cerevel Shareholders to Inquire About Ongoing Investigation into the $45 Merger Offer
-
CAE (NYSE) INVESTOR ALERT: CAE, Inc. Investigated for Securities Fraud from Impairment Charges, Contact BFA Law if You Suffered Losses
